CYP3A4 and breast cancer: In the same way, PXR agonists, like rifampicin and DDF, a FSK analog devoid of adenylate cyclase activation property31, partially promoted the formation of BC; they additionally enhanced the expression of CYP3A4, well-known to be a reference PXR target36.